Sun Pharma Q4 results: Sun Pharmaceutical Industries, a speciality generic pharmaceutical company, will declare its latest set of numbers for the January-March quarter of the financial year 2025-26 on May 22.
In an exchange filing, the company said that its board of directors will meet on Friday, May 22, to "consider and approve audited standalone and consolidated financial results for the quarter and year ended 31 March 2026."
The board will also consider and recommend the final dividend, if any, for FY26 for approval of the shareholders at the forthcoming annual general meeting (AGM).
Sun Pharma Q4 results date and time
Sun Pharma will announce the fourth quarter FY26 results and recommend a dividend, if any, on Friday, May 22, 2026. The pharmaceuticals player has not announced the time to release its results. In Q3, earnings were released during the market hours.
Sun Pharma share price
Shares of Sun Pharma were trading flat at ₹1,871.60, down 0.06%, apiece on the NSE on Tuesday, May 12 at 11:32 am. Its market capitalisation stands at ₹4,49,107.52 crore.
The stock had hit its 52-week high of ₹1,885.80 per share on May 11, 2026, while its 52-week low of ₹1,548 apiece was recorded on September 26, 2025.
The scrip has gained 2.78% in the past week and 13.09% in a month. Year-to-date, it has advanced 8.74%.
Hyundai India versus Maruti:Here is how two auto giants performed in March quarter
How did Sun Pharma perform in Q3 FY26?
The consolidated net profit of Sun Pharmaceutical Industries rose 16.03% to ₹3,368.81 crore in Q3 FY26 as against ₹2,903.38 crore in the same period of the previous fiscal year.
Its consolidated revenue from operations surged 13.49% to ₹15,520.54 crore in the December quarter of the financial year 2025-26, compared to ₹13,675.46 crore in the year-ago period.
The company's earnings before interest, tax, depreciation and amortisation (EBITDA) stood at ₹4,984.4 crore, reflecting an increase of 23.4% from ₹4,009 crore a year back.